The work presented in this manuscript was aimed at identifying how the APL-like post-translational loss of N-CoR could contribute to the pathogenesis of AML-M5 and to illustrate the potential of N-CoR as a novel molecular target in AML-M5 therapy. This evidence concerns the gene NCOR1 and acute myeloid leukemia.